无锡祥生医疗科技股份有限公司 董事会议事规则 第一条 宗旨 公司证券事务部负责处理董事会日常事务。 董事会秘书兼任公司证券事务部负责人, 保管董事会印章。 第四条 董事会专门委员会 公司董事会设立战略委员会、审计委员会、提名委员会、薪酬与考核委 员会, 公司董事会还可根据需要设立其他委员会。专门委员会由不少于 三名董事组成, 审计、提名、薪酬与考核委员会中独立董事应当过半数 并担任召集人, 且审计委员会中应有一名会计专业的独立董事并担任 召集人。 各专门委员会对董事会负责, 其提案应提交董事会审查决定。 1 为了进一步规范无锡祥生医疗科技股份有限公司(以下简称"公司")董 事会的议事方式和决策程序, 促使董事和董事会有效地履行其职责, 提 高董事会规范运作和科学决策水平, 根据《中华人民共和国公司法》、 《上市公司治理准则》、《上海证券交易所科创板股票上市规则》(以下 简称"《上市规则》")以及《无锡祥生医疗科技股份有限公司章程》(以 下简称"公司章程")等有关规定, 制定本规则。 第二条 董事会的组成 公司依法设立董事会。董事会由六名董事组成, 其中独立董事两名, 设 董事长一名。 第三条 证券事务部 第五 ...

Group 1 - The core viewpoint of the news is that Xiangsheng Medical's stock has experienced a decline of 5.03%, with a current price of 32.10 CNY per share and a total market capitalization of 3.599 billion CNY [1] - Xiangsheng Medical, established on January 30, 1996, specializes in the research, manufacturing, and sales of ultrasound medical imaging equipment, with 91.12% of its revenue coming from this segment [1] - The company is located in Wuxi, Jiangsu Province, and was listed on December 3, 2019 [1] Group 2 - According to fund holdings, Wan Jia Fund has a significant position in Xiangsheng Medical, with its Wan Jia Medical Quantitative Stock Mixed Fund A (020491) holding 9,400 shares, representing 1.95% of the fund's net value [2] - The fund has reported a year-to-date return of 29.76% and a one-year return of 56.72%, ranking 1937 out of 8190 and 1830 out of 7966 respectively [2] - The fund manager, Yin Hang, has been in position for 5 years and 40 days, with the fund's total asset size at 468 million CNY [3]

Core Viewpoint - Xiangsheng Medical (688358) has shown a price increase of 2.44% this week, closing at 34.06 yuan, indicating positive market sentiment despite the lack of share reduction by major shareholders [1] Company Summary - As of August 22, 2025, Xiangsheng Medical's total market capitalization is 3.819 billion yuan, ranking 100th out of 126 in the medical device sector and 4012th out of 5152 in the A-share market [1] - The stock reached a weekly high of 34.53 yuan on August 21 and a low of 33.01 yuan on August 18 [1] Shareholder Activity - The shareholder reduction plan for Xiangsheng Medical has expired without any shares being sold by major shareholders, including Xiangding Investment, Shanghai Yude, and Xiangpeng Investment, who had planned to reduce their holdings by a total of 1,176,000 shares, 419,989 shares, and 336,000 shares respectively [1] - The shares in question are unrestricted circulating shares obtained prior to the company's initial public offering and through capital reserve conversion [1]

祥生医疗8月22日股价报收34.06元，较前一交易日上涨1.25%。盘中最高触及34.30元，最低33.74元，成 交金额达0.48亿元。 从资金流向来看，8月22日主力资金净流出442万元，近五个交易日累计净流出1100.5万元。当前公司总 市值38.19亿元，市净率为2.83。 来源：金融界 该公司属于医疗器械板块，主营业务为超声医学影像设备的研发、生产和销售。作为一家高新技术企 业，祥生医疗专注于超声医学影像领域的技术创新和产品开发。 风险提示：股市有风险，投资需谨慎。 ...

Core Insights - The article highlights the rapid evolution of ultrasound diagnostic equipment towards intelligence and portability, with Xiangsheng Medical emerging as a representative enterprise in technological innovation and market expansion in the ultrasound AI field [1] Group 1: Technological Innovation - Xiangsheng Medical has positioned itself as a pioneer in the domestic ultrasound AI diagnostic sector, leveraging AI technology to enhance traditional ultrasound practices [2] - The company employs a dual-engine approach of "ultrasound artificial intelligence + specialized models" to drive innovation across various scenarios, establishing a comprehensive intelligent framework that covers device development, image acquisition, and diagnostic decision-making [2] - The company has achieved significant advancements in AI-assisted diagnostic technologies across multiple fields, including breast, liver, and cardiovascular diseases, with its breast ultrasound analysis software receiving medical device registration approval in 2022 [2] Group 2: Product Development and Applications - Xiangsheng Medical has launched the "Breast Artificial Intelligence Ultrasound Robot" system to address the challenges of mass screening for breast cancer in China, integrating ultrasound imaging, robotics, and AI technology into a comprehensive health management model [3] - The system features an original integrated design that includes a touchscreen, electric examination bed, six-degree-of-freedom robotic arm, and AI-assisted diagnostic capabilities, facilitating large-scale efficient scanning and data tracking for breast cancer prevention and treatment [3] Group 3: Market Expansion and New Applications - The company is actively exploring new ultrasound application scenarios, achieving breakthroughs in areas such as helicopter medical rescue, precision aesthetic medicine, and veterinary ultrasound [4] - Xiangsheng Medical provided medical support at major sporting events, utilizing its self-developed 5G remote consultation system and portable ultrasound devices to enhance emergency response efficiency [4] - The company is expanding its portable intelligent product offerings in the aesthetic medicine sector and has entered various domestic and international medical institutions, including partnerships with notable organizations like the Gates Foundation for project funding [5]

Group 1 - The core viewpoint of the article highlights the performance of the Science and Technology Innovation Enhanced ETF (588520), which opened with a gain of 0.67% at 1.195 yuan [1] - The top holdings of the ETF include companies such as SMIC, which rose by 1.59%, and Cambricon, which increased by 3.76%, while others like Jianyuan Technology and Transsion Holdings experienced slight declines [1] - The ETF's performance benchmark is the Shanghai Stock Exchange Science and Technology Innovation Board Composite Price Index, managed by Yongying Fund Management Company, with a return of 18.66% since its inception on June 27, 2025, and a return of 13.59% over the past month [1]

证券代码：688358 证券简称：祥生医疗 公告编号：2025-020 无锡祥生医疗科技股份有限公司 股东减持计划时间届满暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次减持股东的基本情况 本次减持计划实施前，无锡祥生医疗科技股份有限公司（以下简称"祥生医疗"或"公司"）股东无锡祥鼎 投资企业（有限合伙）（以下简称"祥鼎投资"）持有公司股份4,704,000股，占公司总股本的4.20%；股 东上海御德科技有限公司（以下简称"上海御德"）持有公司股份1,679,956股，占公司总股本的1.50%； 股东无锡祥鹏投资企业（有限合伙）（以下简称"祥鹏投资"）持有公司股份1,344,000股，占公司总股本 的1.20%。 上述股份均为无限售流通股，来源于公司首次公开发行前取得的股份以及公司实施资本公积转增股本取 得的股份，涉及公司首次公开发行前取得的股份已于2022年12月3日解除限售并上市流通。 ● 减持计划的实施结果情况 ■ 上述减持主体存在一致行动人： ■ 二、减持计划的 ...

祥生医疗主营业务为医疗器械的研发、生产和销售，产品涵盖超声诊断设备及相关技术服务。公司2024 年年报显示，医疗器械业务收入占比达99.88%。 截至2025年8月21日收盘，祥生医疗股价报33.64元，较前一交易日下跌1.52%。当日成交额为0.42亿 元，换手率为1.09%。 公司8月21日晚间公告显示，股东祥鼎投资、上海御德、祥鹏投资的减持计划期限已届满，期间上述股 东未实施减持。根据公开数据，祥生医疗当日主力资金净流出319.18万元，近五日主力资金累计净流出 2339.86万元。 风险提示：股市有风险，投资需谨慎。 来源：金融界 ...

（以下简称"祥鹏投资"）持有公司股份 1,344,000 证券代码：688358 证券简称：祥生医疗 公告编号：2025-020 无锡祥生医疗科技股份有限公司 股东减持计划时间届满暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： ? 本次减持股东的基本情况 本次减持计划实施前，无锡祥生医疗科技股份有限公司（以下简称"祥生医 疗"或"公司"）股东无锡祥鼎投资企业（有限合伙） （以下简称"祥鼎投资"）持有 公司股份 4,704,000 股，占公司总股本的 4.20%；股东上海御德科技有限公司（以 下简称"上海御德"）持有公司股份 1,679,956 股，占公司总股本的 1.50%；股东 无锡祥鹏投资企业（有限合伙） 股，占公司总股本的 1.20%。 上述股份均为无限售流通股，来源于公司首次公开发行前取得的股份以及公 司实施资本公积转增股本取得的股份，涉及公司首次公开发行前取得的股份已于 ? 减持计划的实施结果情况 股份计划公告》，公司股东祥鼎投资拟自减持计划公告披露之日起 15 个 ...

每经AI快讯，祥生医疗（SH 688358，收盘价：33.64元）8月21日晚间发布公告称，近日，公司收到上 述减持主体的告知函，截至2025年8月21日，上述减持计划时间已届满，在减持计划期限内，公司股东 祥鼎投资、上海御德、祥鹏投资未减持公司股份。 （记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 2024年1至12月份，祥生医疗的营业收入构成为：医疗器械行业占比99.88%，其他业务占比0.12%。 截至发稿，祥生医疗市值为38亿元。 每经头条（nbdtoutiao）——最火游资不再是方新侠、章盟主、佛山无影脚？这名95后声名鹊起！ ...